Gilead (GILD) Director Jeffrey Bluestone Exercises Options, Sells Shares

What Happened

• Jeffrey Bluestone, a director of Gilead Sciences (GILD), exercised stock options to acquire a total of 5,000 shares (strikes $61.35 and $67.45) and immediately sold those shares in open-market transactions. Exercise cost shown: ~$335,206; gross sale proceeds shown: ~$725,077; net cash roughly $390K.
• The exercises and sales occurred on August 20, 2026. The sales were executed at prices in the approximately $143.31–$146.36 range.

Key Details

• Transaction date: August 20, 2026. Form filed Aug 21, 2026 (appears timely).
• Exercise details: 5,000 shares acquired via option exercises (lots at $61.35 and $67.45). Total reported exercise payment ≈ $335,206.
• Sales: 5,000 shares sold in multiple open-market transactions for total reported proceeds ≈ $725,077 (per-share sales ranged roughly $143–$146).
• Footnotes: Transaction was executed pursuant to a Rule 10b5‑1 trading plan adopted May 20, 2026 (F1). Sale price groupings and exact per-lot prices are broken out in footnotes (F2–F4). Footnotes F5 and F6 note that the underlying options were fully vested (either via scheduled vesting or immediate vesting on grant).
• Shares owned after the reported transactions are not provided in the data shown here.
• Form shows derivative "disposed" line items at $0 for 4,665 and 335 shares; such entries commonly reflect share surrender/netting or other exercise-related adjustments.

Context

• This was an exercise of options followed by immediate open-market sales (a common cashless exercise pattern). That typically converts option value to cash rather than signaling a change in the director’s long-term view.
• The trades were executed under a pre-established 10b5‑1 plan, which is designed to limit timing discretion by the insider.
• These are insider transactions by a director, not a 10% owner purchase; they are informative but not by themselves a definitive signal of company prospects.